44 citations
,
April 2015 in “PubMed” This study reports that clinical trials of finasteride for androgenic alopecia provide insufficient and systematically biased safety data, with most participants unrepresentative of those in pivotal trials that led to FDA approval.
97 citations
,
January 2014 in “Journal of The American Academy of Dermatology” This study found that dutasteride increased hair growth and restoration in men with androgenetic alopecia more effectively than finasteride and was well tolerated over 24 weeks.
66 citations
,
June 2013 in “Journal of Dermatological Treatment” This study reported no significant difference in efficacy or sexual dysfunction risk between 5α-reductase inhibitors and placebo for androgenetic alopecia, suggesting that dutasteride 0.5 mg may be considered pending further research.
59 citations
,
January 2011 in “Retina-the Journal of Retinal and Vitreous Diseases” This study suggests that finasteride may be a promising treatment for chronic central serous chorioretinopathy, but larger controlled trials are needed to confirm its efficacy.
113 citations
,
April 1999 in “The Journal of Clinical Endocrinology and Metabolism” This study found that all four treatments—flutamide, finasteride, ketoconazole, and EE-CPA—significantly reduced hirsutism, but EE-CPA and flutamide appeared most effective, with varying effects on androgen levels and side-effect profiles.